← All organizations
Highest phase reached
Phase 2
First clinical trial
May 29, 2024Last known activity
May 29, 2025
Timeline
No events for the selected filters.
Drugs by trial phase (16 distinct, 14 trials)
Phase 2 (16 own, 0 via acquisition)
- autologous tumor infiltrating lymphocytes
- aldesleukin
- pembrolizumab
- cyclophosphamide
- mesothelin car t cells
- cd33 car-t cells
- fludarabine
- gpc3 car-t cell
- autologous cd19/cd22 chimeric antigen receptor t-cells
- cd123 car-t cells
- cd7 car-t cell
- car-cldn18.2 t-cells
- bcma/cd19 dual-target car-t
- cd5 car-t cells
- anti-bcma/gprc5d car-t cell
- +1 more
Recent trials (14)
- NCT07066982Lead sponsorPhase 1/Phase 2May 29, 2025
- NCT07066995Lead sponsorPhase 1/Phase 2Apr 29, 2025
- NCT07032129Lead sponsorPhase 1/Phase 2Apr 29, 2025
- NCT07067255Lead sponsorPhase 1/Phase 2Apr 29, 2025
- NCT06640582Lead sponsorPhase 1/Phase 2Oct 20, 2024
- NCT06530303Lead sponsorPhase 1/Phase 2Sep 29, 2024
- NCT06532799Lead sponsorPhase 1/Phase 2Sep 10, 2024
- NCT06532812Lead sponsorPhase 1/Phase 2Aug 22, 2024
- NCT06538012Lead sponsorPhase 1/Phase 2Aug 20, 2024
- NCT06213636Lead sponsorPhase 1/Phase 2Jul 10, 2024
- NCT06350110Lead sponsorPhase 1/Phase 2Jul 10, 2024
- NCT06420063Lead sponsorPhase 1/Phase 2Jul 10, 2024
- NCT06420076Lead sponsorPhase 1/Phase 2Jul 10, 2024
- NCT06428188Lead sponsorPhase 1/Phase 2May 29, 2024
Details
- Last known activity
- May 29, 2025